Cystic Fibrosis Pipeline Insights 2025 Market - 2026-2032

May 2026 | - | ID: C231205C3B21EN
DataM Intelligence

Contents

1. EXECUTIVE SUMMARY

1.1. Introduction

2. CYSTIC FIBROSIS: OVERVIEW

2.1. Introduction
2.2. Causes
2.3. Pathophysiology
2.4. Signs and Symptoms
2.5. Diagnosis
2.6. Treatment

3. PIPELINE ANALYSIS

3.1. Assessment by Phase
  3.1.1. Phase I Clinical Trials
  3.1.2. Phase II Clinical Trials
  3.1.3. Phase III Clinical Trials
3.2. Assessment by Mechanism of Action
  3.2.1. CFTR Modulators
  3.2.2. Gene Therapy & RNA-Based Therapies
  3.2.3. Anti-Infective Therapies
  3.2.4. Anti-Inflammatory & Immunomodulators
  3.2.5. Others
3.3. Assessment by Route of Administration
  3.3.1. Oral
  3.3.2. Inhalation
  3.3.3. Intravenous
3.4. List of Key Companies Involved
3.5. Vertex Pharmaceuticals Incorporated*
  3.5.1. Detailed Drug Profile
3.6. Spirovant Sciences, Inc.
3.7. SpliSense Ltd.
3.8. Enterprise Therapeutics Ltd
3.9. Boehringer Ingelheim International GmbH
3.10. 4D Molecular Therapeutics
3.11. Clarametyx Biosciences, Inc.
3.12. Arcturus Therapeutics, Inc.
3.13. Krystal Biotech, Inc.
3.14. Cystetic Medicines, Inc.
3.15. Kither Biotech Srl
3.16. ReCode Therapeutics

4. REGULATORY DESIGNATIONS

4.1. Orphan Drug Designation
4.2. Fastrack Designation
4.3. Breakthrough Therapy Designation
4.4. Priority Review
4.5. PRIME Designation
4.6. RMAT Designation
4.7. ATMP Designation

5. CLINICAL DATA READOUTS

5.1. Trial Initiation
5.2. Trial Completion
5.3. Safety/Efficacy- Data Readouts
5.4. Discontinued Products

6. ESTIMATED APPROVALS

7. MERGER AND ACQUISITIONS

8. FUTURE PERSPECTIVES AND CONCLUSION